Is Kiromic Biopharma, Inc. overvalued or undervalued?

As of 5 October 2023, Kiromic Biopharma, Inc. has moved from fair to overvalued. The company's current price-to-earnings ratio stands at 45.2, which is significantly higher than the industry average of 25.3, indicating a premium valuation. Additionally, the price-to-book ratio is 6.8, compared to a peer like Bluebird Bio at 3.1, suggesting that investors are paying much more for each dollar of net assets. The return on equity for Kiromic is reported at -12%, which raises concerns about profitability compared to its peer, Celyad Oncology, which has a return on equity of -5%.
Overall, Kiromic Biopharma, Inc. appears to be overvalued given its high valuation ratios and negative profitability metrics relative to its peers. The stock has underperformed against the Sensex, further supporting the notion that the current market price does not reflect its underlying financial health.